Evidence map›Paper›PMID 12525632›Full record

ArticleJournal of virology2003

Replication of human immunodeficiency viruses engineered with heterologous Tat-transactivation response element interactions.

Baode Xie, Mark A Wainberg, Alan D Frankel

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Protein post-translational modifications:Computational and structural biotechnology journal · 2017
    Review
  3. Tat acetylation modulates assembly of a viral-host RNA-protein transcription complex.Proceedings of the National Academy of Sciences of the United States of America · 2009
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Baode XieDepartment of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, California 94143-0448, USA.
Mark A Wainberg
Alan D Frankel
University of California, San Francisco · USMcGill University · CA

Funding

ACTIVITY AND INHIBITION OF THE TAT PROTEIN FROM HIVR01AI029135 · NIAID · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI FRANKEL, ALAN D · 1989 to 2010
$2.8M
STATISTICAL PROBLEMS IN AIDS STUDIESR01AI029131 · NIAID · UNIVERSITY OF WISCONSIN MADISON · PI WEI, LEE-JEN · 1989 to 1991
–
NIAID NIH HHS R01 AI029135NIAID NIH HHS R01 AI29131
6 · The paper itself

Abstract

Human immunodeficiency viruses (HIVs) and the related bovine lentiviruses bovine immunodeficiency virus (BIV) and Jembrana disease virus (JDV) utilize the viral Tat protein to activate viral transcription. The arginine-rich RNA-binding domains of the Tat proteins bind to their cognate transactivation response element (TAR) RNA hairpins located at the 5' ends of the viral mRNAs, resulting in enhanced processivity of RNA polymerase II. It has previously been shown that HIV type 1 (HIV-1) Tat requires the cellular cyclin T1 protein for high-affinity RNA binding whereas BIV Tat and JDV Tat bind with high affinity on their own and adopt distinct beta-hairpin conformations when complexed to RNA. Here we have engineered the BIV and JDV Tat-TAR interactions into HIV-1 and show that the heterologous interactions support viral replication, correlating well with their RNA-binding affinities. Viruses engineered with a variant TAR able to bind all three Tat proteins replicate efficiently with any of the proteins. In one virus containing a noncognate Tat-TAR pair that neither interacts nor efficiently replicates (HIV-1 TAR and BIV Tat), viral revertants were isolated in which TAR had become mutated to generate a functional BIV Tat binding site. Our results support the view that incremental changes to TAR structure can provide routes for evolving new Tat-TAR complexes while maintaining active viral replication.

Indexed as

Virus ReplicationAmino Acid SequenceBinding SitesCell LineGene Products, tatGenetic EngineeringHIV-1HIV Long Terminal RepeatHumansImmunodeficiency Virus, BovineMolecular Sequence DataResponse ElementsRNA, Viraltat Gene Products, Human Immunodeficiency VirusTranscriptional ActivationGene Products, tatRNA, Viraltat Gene Products, Human Immunodeficiency Virus

Identifiers

PMID12525632
PMCPMC140932
OpenAlexW2124651403

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.